terminal

Oxytocin C-terminal tripeptide Acetate is the C-terminal tripeptide of Oxytocin.Oxytocin is a mammalian neuropituitary hormone, a ligand for the oxytocin receptor.

Fas C-Terminal Tripeptide Acetate shows inhibitory activity of Fas/FAP-1 binding.

Amyloid precursor c-terminal peptide has the amino acid sequence Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn. APP is best known as the precursor molecule whose proteolysis generates beta-amyloid (Aβ), a 37 to 49 amino acid peptide whose am

Clathrin-IN-1 is a inhibitor of clathrin, and inhibits clathrin-mediated endocytosis (CME) by associating with the terminal domain of clathrin. It has the potential for anti-cancer research.

Methacycline hydrochloride (Rondomycin) is a broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.

5,5-Dimethyloxazolidine-2,4-dione (Dimethadione) is an anticonvulsant that is the active metabolite of TRIMETHADIONE.

FGTI-2734 is a dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor, exhibiting IC50 values of 250 nM and 520 nM for FT and GGT-1, respectively. It effectively prevents the membrane localization of KRAS, addressing the issue of KRAS resistance and inhibiting the growth of mutant KRAS patient-derived pancreatic tumors.

Src Inhibitor 3 is an effective inhibitor of c-terminal Src kinase (IC50 <3 nM in CSK HTRF, <4 nM in Caliper assay). Src Inhibitor 3 increases T cell proliferation induced by T cell receptor signaling.

TCID (UCH-L3 Inhibitor)(IC50=0.6 μM) is a DUB inhibitor of ubiquitin C-terminal hydrolase L3. It has the 125-fold selectivity to L1.

EPI-001 is an androgen receptor N-terminal domain antagonist with IC50 of ～6 μM and a selective PPAR-gamma modulator.

I-BRD9 (GSK602) is the first selective cellular inhibitor for BRD9 with pIC50 of 7.3.

Proadrenomedullin N-terminal 12 peptide (PAMP-12), an endogenous fragment originating from the adrenal medulla and spanning amino acids 9-20 of human PAMP-20, plays a role in causing hypotension. It functions as an agonist for the MAS-related G protein-coupled receptor family member X2 (MRGPRX2), inhibiting forskolin-stimulated cAMP accumulation in CHO cells expressing human MRGPRX2 (EC50 = 57.2 nM) and selectively prompting calcium mobilization in these cells (EC50 = 41 nM), but not in cells expressing MRGPRX1, MRGPRX3, or MRGPRX4 at 1 µM. As an antagonist of nicotinic acetylcholine receptors (nAChRs), PAMP-12 obstructs carbachol-triggered catecholamine release and the influx of calcium and sodium (IC50s = 1.3, 0.39, and 0.87 µM, respectively) in primary bovine adrenal chromaffin cells, with no effect on histamine-induced responses (IC50s = >1 µM for all). Additionally, it decreases mean arterial blood pressure in normotensive rats at doses ranging from 10 to 50 nmol/kg.

CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.

Sphistin Synthetic Peptide is a truncated fragments of Sphistin Synthetic Peptide that shows potent antimicrobial activity.

Gastrin hexapeptide is a hexapeptide from porcine antral mucosa.

NEP(1-40), N-terminal uncapped, is an analog of NEP(1-40) without acetylation at the N-terminus. NEP(1-40) acts as a peptide antagonist of the Nogo-66 receptor (NgR).

Cemdisiran, an investigational N-acetylgalactosamine-conjugated RNAi (RNA interference) agent with terminal sugar modification, is a small interfering RNA (siRNA) designed to specifically target and suppress the C5 mRNA, thereby reducing the liver's production of the complement component C5 [1].

Sphistin Synthetic Peptide (12-38, Fitc in N-Terminal-Fluorescently Labeled Peptide) represents truncated fragments of the parent peptide, characterized by an N-terminal fluorescent label (Fitc).

VPS35 c-terminal peptide is a peptide that binds to VPS35. In immunoprecipitation assays, it can be used to specifically elute VPS35 and its interacting proteins, aiding in the identification of VPS35 interaction molecules.

Terminal Transferase, Calf (EC 2.7.7.31) is a template-independent polymerase that catalyzes the addition of deoxynucleotides to the 3' hydroxyl ends of DNA molecules. It can utilize double-stranded or single-stranded DNA with protruding, recessed, or blunt ends as substrates. Terminal Transferase, Calf (EC 2.7.7.31) lacks 5' or 3' exonuclease activity. The presence of Co2+ in the reaction can enhance the efficiency of end addition.

Secretin (1-6) is the N-terminal part of secretin. It can produce vitro glucose-dependent insulin release induced by secretin.

Terminal deoxyribonucleotidyltransferase (TdT) catalyzes the addition of deoxyribonucleotide triphosphates to the 3' hydroxyl terminus of a DNA chain and introduces N regions at gene segment junctions during V(D)J recombination. It is expressed in immature, pre-B, and pre-T lymphocytes, as well as in acute lymphoblastic leukemia/lymphoma cells.

Leu-enkephalin, an endogenous peptide consisting of five amino acids, functions as an agonist at opioid receptors. The N-terminally acetylated form of this compound is known as N-terminally acetylated Leu-enkephalin.

N-terminally acetylated Endomorphin-1 acetate (Ac-L-Tyr-L-Pro-L-Trp-L-Phe-CONH2) is a modified Endomorphin-1.